Cereius is a Durham, NC–based biotechnology company focused on novel approaches to treat solid tumor brain metastases. The company was founded in 2017 by Dr. Michael Zalutsky and Dr. Kimberly Blackwell and is led by CEO Ed Field. Its intellectual property includes next‑generation radiolabeling chemistries developed by Dr. Zalutsky and exclusively licensed from Duke University. These chemistries are designed to increase uptake and retention of radionuclides in target tumors while minimizing uptake by normal tissues, thereby enhancing therapeutic index and diagnostic contrast. Cereius recently closed a $6.75M financing (a $6.5M Series A plus a $250k loan), strengthening its financial position. Governance will be bolstered by new board members tied to investors and industry, signaling active investor engagement.

Total raised

$7M

Funding rounds

2

Latest round

Series A

Latest activity

Jul 2018